Gilead Sciences is acquiring Arcellx in a deal valued at up to $7.8 billion, gaining full control of its CAR-T therapy candidate for multiple myeloma and strengthening its oncology pipeline.
Boehringer Ingelheim India has signed a landmark MoU with NIPER Raebareli to advance pharmaceutical innovation, strengthen research in novel drug delivery systems, and support academic collaboration in India’s evolving healthcare ecosystem.
BahiaFarma has joined hands with Biocon Biologics and Bionovis to develop and manufacture Pertuzumab for HER2-positive breast cancer, strengthening Brazil’s public healthcare supply and deepening India-Brazil pharma collaboration.
Merck and Mayo Clinic have joined forces in a major AI-driven research deal aimed at reshaping drug discovery. The collaboration blends advanced analytics, genomic data, and clinical expertise to speed up new therapy development.
Samsung Health partners with PharmEasy & Tata 1mg to launch ‘Find Care’ feature, offering seamless access to healthcare services like tests, doctor consultations, and medicine orders.
Roche has announced a major breakthrough in primary membranous nephropathy after its Phase III MAJESTY trial showed higher complete remission rates with Gazyva/Gazyvaro compared to tacrolimus, marking a potential shift in rare kidney disease care.
Rx Propellant is scaling up in Genome Valley with a USD 100 million investment in a new life sciences campus. The move strengthens Hyderabad’s global biotech standing and meets rising demand for advanced lab space.
Aster Volunteers launches two new Mobile Medical Units in Tirupati and Anekal, expanding healthcare access in underserved communities across India.
Courage met opportunity in Haridwar as Akums hosted a three-day skill camp for acid attack and burn survivors, helping them step into corporate life with confidence and purpose.
Indian pharma leaders Sun Pharma and Glenmark are adopting AI in drug discovery to reduce costs, accelerate R&D timelines, and move from generics toward innovative medicines.